Cambrian Bio Appoints Veteran Biotech Executive Bill DeVaul as Chief Legal Officer

New York, New York - April 21, 2026 - Cambrian Bio, a clinical-stage drug development company whose pipeline platforms include therapeutics targeting critical metabolic pathways that decline with age, today announced the appointment of William (Bill) DeVaul as Chief Legal Officer.

‍

"Bill is an experienced leader who has guided companies through major financings, public listings, and complex strategic partnerships over the last two decades," said James Peyer, CEO and Founder of Cambrian Bio. "We are excited to add his expertise to our team and look forward to the impact he will make as we advance our pipeline targeting the drivers of metabolic dysfunction."

‍

In his role, Bill will oversee all legal, compliance, and governance matters across Cambrian and its programs, providing strategic counsel to the executive team on corporate operations, partnerships, and transactions. He will also lead the company's intellectual property strategy in close collaboration with its scientific and business teams.

‍

"I'm thrilled to be joining Cambrian at such a pivotal moment in the company's development," said Bill DeVaul. "The science is compelling, the mission is important, and the team has done an exceptional job advancing the pipeline. I look forward to contributing to the legal and operational foundation to improve the lives of patients."

‍

Bill brings over 20 years of biotech legal experience spanning intellectual property, corporate governance, M&A, and strategic partnerships. Most recently, he served as General Counsel, Chief Compliance Officer, and Corporate Secretary at Morphic Holding, where he led the company from private stage through its IPO, major financings, high-value collaborations, and eventual acquisition for $3.2B. Previously, he was Vice President of Intellectual Property at Evelo Biosciences, supporting its IPO as sole in-house counsel, and held senior legal roles at Cubist Pharmaceuticals, where he managed a large team covering complex litigation, healthcare regulation, and multiple acquisitions. In private practice early in his career, Bill represented research institutions, biotech companies, and Nobel laureates.

‍

About Cambrian Bio

‍

Cambrian Bio is a clinical-stage drug development company focused on building therapeutics to treat and ultimately prevent some of today's most debilitating chronic diseases, including platforms targeting critical metabolic pathways that decline with age such as AMPK, mitochondrial activation, and mTOR. To learn more, visit https://www.CambrianBio.com and follow us on LinkedIn.